At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Transcranial Photobiomodulation for Reducing Autism Symptoms in Children.
In Brief
A clinical study evaluating Cognilum TM: Light Treatment Condition for Autism Spectrum Disorder. Completed, enrolled 25 participants across 2 sites.
Detailed Summary
The hypothesis of the study is that photobiomodulation reduces symptoms of autism. Participants will be children between the ages of 2 and 7, who have been diagnosed with moderate to severe autism. Transcranial photobiomodulation will be administered to the children in the experimental condition twice a week for 10 weeks. Results will be measured through parental interviews, standardized CARS2 (Childhood Autism Rating Scales, 2nd Edition) and data collected from EEG.
Study Details
Timeline
Interventions
The children will wear the CognilumTM device for up to 15 minutes at a time, twice a week, for a period of 10 weeks.